(Date:12/2/2009)... Martek Biosciences Corporation (Nasdaq: MATK ) announced today ... quarter and fiscal year 2009 on December 16, 2009, at ... at 4:45 p.m. ET Martek will conduct a conference call ... may listen to the call live via webcast by visiting ...
(Date:12/2/2009)... YORK, Dec. 2 Nearly 600 medical research executives, ... novel development approaches and innovative funding strategies at the ... FasterCures, the Washington-based center of the Milken ... multi-sector collaborations needed to turn a scientific discovery into ...
(Date:12/2/2009)... Holding NV,the Netherlands based biotechnology company focusing on protein ... that it,has appointed Wim E.M. Mol, Ph.D. as new ... Mol will be responsible for all of Pepscans corporate ... company. He brings to,Pepscan more than 20 years of ...
(Date:12/2/2009)... Dec. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,("Simcere" or ... leading pharmaceutical company,specializing in the development, manufacturing, and ... today announced that 105 of,its drugs have been ... was issued by China,s Ministry of Human Resources ...
Breaking Biology Technology:Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Dutch Biotech Company Pepscan Appoints New CEO 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3... LAGUNA HILLS, Calif., Nov. 20 CalbaTech, Inc.,(OTC BB: ... concentrating on the collection and banking of adult stem ... platforms to,the biotech and pharmaceutical research markets and to ... U.S. Securities &,Exchange Commission that it anticipates to be ...
... GeneGo, Inc., the leading,provider of databases, software ... Utrecht University will be using MetaDrug in ... is designed for predicting,biological effects such as ... structures. Its content includes xenobiotics with known,activity, ...
... 20 /PRNewswire/ - Cytochroma Inc. announced today,that it ... trial of CTAP101,Capsules, the Company,s product candidate for ... disease (CKD). This Phase I/II clinical trial ... the pharmacokinetic profile and safety of CTAP101,Capsules in ...
Other Biology Technology:CalbaTech Files Nine Month Financial Results; Anticipates Profitability in 2007 2CalbaTech Files Nine Month Financial Results; Anticipates Profitability in 2007 3Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation 2Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease 2PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....
Human/Mouse/Rat p38 alpha Affinity Purified PAb...
XBP1 Antibody...
Recombinant Mouse LIGHT/TNFSF14...
Biology Products: